Celmatix

Did you know that the male is solely responsible in?about 20% of cases?and is a contributing factor in another 30% to 40% of all infertility cases? At Celmatix our oral FSHR agonist offers a promising alternative that could improve compliance and efficacy for both male and female infertility treatments. Great read by Priya Oberoi:

What a special day! We are so proud to be featured on the Nasdaq screen in Times Square! ?? The entire Celmatix team has been working so hard to transform women’s lives through better ovarian health. More to come soon! CC: Advanced Research Projects Agency for Health (ARPA-H) Piraye Beim stephen palmer Charlotte Frank Sage, PhD Craig Bolton Caterina Clementi Lei Tan

Exciting news! ?? New episodes of Boss Ovary are on the way! Get ready for insightful conversations with our CEO & Founder, Piraye Beim, as well as industry-leading physicians, scientists, entrepreneurs, and more.?Subscribe here: https://lnkd.in/dWRNyZ-k

Have you seen our latest news? We just reached a major milestone in our oral fertility drug program ?? ! With infertility affecting 1 in 6 people worldwide, and minimal innovation in this space for decades, Celmatix’s oral FSHR agonist can be a game-changer, offering a non-invasive, patient-friendly alternative.?This represents a major milestone, with the potential to transform fertility treatments for both men and women! What does this mean? We’re working to create a future where we can replace traditional hormone injections with oral medications. ?? Read the full news here: https://lnkd.in/d-EGPG9a CC: stephen palmer

We could not be more proud to share that Celmatix has been selected by the?Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the?Sprint for Women’s Health, to address critical unmet challenges in women’s health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women! "The research effort is led by Dr. Piraye Beim Yurttas Beim, founder and CEO, and Dr. stephen palmer, chief scientific officer, of Celmatix and will fund the company's ongoing efforts to develop a therapeutic aimed at controlling the timing and rate of decline in ovarian function that occurs in women during perimenopause and menopause. Menopause is the single biggest accelerant of unhealthy aging for modern women and helps explain why women are disproportionately impacted postmenopausally with conditions like heart disease and stroke, autoimmune disorders, osteoporosis, and Alzheimer’s disease. Despite the negative impacts of menopause on the health of all women at mid-life and beyond, there are currently no therapeutic interventions that enable women to proactively manage their lifelong health by controlling the timing of the onset of menopause or the rate of decline of ovarian function leading to menopause." Huge congratulations to our team. Without all of you, this would not be possible! Learn more below: Celmatix Press Release: https://lnkd.in/d9qCDw_6 ARPA-H Press Release: https://lnkd.in/dV_UmKhg

Big news for Celmatix! Our team just reached a significant milestone in our oral Follicle Stimulating Hormone (FSHR) agonist drug program. We've successfully nominated our lead compound, which has shown oral bioavailability and biological activity in preclinical models. This brings us one step closer to offering a non-invasive alternative to traditional hormone injections for fertility treatments. ?? ?? Read the full details here:

In honor of World Menopause Day, a little #flashbackfriday to our CEO + Founder Piraye Beim speaking at SXSW on Menopause with Heidi Snyder Flagg, Mary Claire Haver, MD, and Tamsen Fadal. They talk about the latest science to understand what’s next in hormone health for women. From cardiovascular health to brain health to sexual wellness, research continues to show the critical role hormones play in women’s health as we age. Check out the full discussion here:

Our CEO and Founder Piraye Beim spoke at Founders Forum Group North America 2024 on the panel "Living Well, Aging Less: The Shift to Preventative Healthcare" alongside Eric Verdin, CEO & President of Buck Institute for Research on Aging, and "Joe Betts-LaCroix", CEO of Retro Biosciences, moderated by Cynthia Koons from Bloomberg! This event was such a great opportunity to connect with so many industry leaders innovating across multiple sectors. Thank you Founders Forum for a memorable day! Ft: David Luu, MD Molly Maloof

"The symptoms associated with menopause — hot flashes, night sweats, mood changes, sleep disturbances, joint aches and cognitive difficulties — cost an estimated $1.8 billion in lost work time in the U.S. annually. That figure rises to $26.6 billion when medical expenses are calculated." Check out the full Mayo Clinic study here: https://lnkd.in/gTs8Vxxu

“People that suspect they have endometriosis or suspect they have some sort of chronic disease, they always have to advocate for themselves, and that’s a crappy position to be in when you’re in terrible amounts of pain,” she says. “You feel defeated. You’ve been told it’s all in your head or whatever, and then you’re supposed to have the fortitude to keep trying to find doctors who might tell you that you’re crazy again.” -Diana Falzone Did you know that One in three women have conditions caused by poor ovarian health. Despite often debilitating symptoms, such conditions are still being treated with hormonal interventions introduced more than 50 years ago. The problem doesn’t stop there. Because the ovary plays a critical role in overall endocrine function, women experience serious health problems?when ovarian function fails. This is why Celmatix is working to transform women’s lives through better ovarian health. Women deserve better! CC: Endometriosis Foundation of America